HIA
AVDL

Harbor Investment Advisory’s Avadel Pharmaceuticals AVDL Stock Holding History

Harbor Investment Advisory’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-200
Closed -$1.57K – 1179
2025
Q1 		$1.57K Hold
200
– – ﹤0.01% 1095
2024
Q4 		$2.1K Hold
200
– – ﹤0.01% 1059
2024
Q3 		$2.62K Hold
200
– – ﹤0.01% 1045
2024
Q2 		$2.81K Hold
200
– – ﹤0.01% 1036
2024
Q1 		$3.38K Hold
200
– – ﹤0.01% 1022
2023
Q4 		$2.82K Hold
200
– – ﹤0.01% 1012
2023
Q3 		$2.06K Hold
200
– – ﹤0.01% 1039
2023
Q2 		$3.3K Hold
200
– – ﹤0.01% 1174
2023
Q1 		$1.83K Buy
+200
New +$1.64K ﹤0.01% 1231

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harbor Investment Advisory's AVDL Position: Q2 2025 in Review

Harbor Investment Advisory sold out of Avadel Pharmaceuticals (AVDL) in Q2 2025, closing a stake of 200 shares — an estimated $1.57K sold.

Harbor Investment Advisory first reported a position in AVDL in Q1 2023 and held it in 9 quarters. The position peaked at $3.38K in Q1 2024. 173 funds tracked by Wall St. Rank hold AVDL as of Q2 2025.

  • Harbor Investment Advisory reported no remaining Avadel Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Harbor Investment Advisory sold 200 Avadel Pharmaceuticals shares in Q2 2025, an estimated $1.57K.
  • Harbor Investment Advisory first reported a position in Avadel Pharmaceuticals in Q1 2023 and held it in 9 quarters.
  • Harbor Investment Advisory's Avadel Pharmaceuticals position peaked at $3.38K in Q1 2024.
  • 173 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2025.

Based on Harbor Investment Advisory's 13F filing for Q2 2025, filed 1 Jul 2025.